Congratulations to Jon and the team.
3 for 3 with the P2 trials with powerful, significant gains across the board.
Outstanding and a credit to their meticulous planning and vision for our pipeline.
Clean air now to the P3 discussions with the FDA, but I would expect BP to put their cards on the table in the very near term now.
And they’ll need a very compelling hand…
Ann: Phase 2 trial shows significant improvements in Angelman, page-55
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.97 |
Change
0.270(2.13%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $13.02 | $13.06 | $12.90 | $3.512M | 270.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 598 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.98 | 792 | 4 |
View Market Depth
| Last trade - 11.48am 17/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |